ContraVir Pharmaceuticals (CTRV) is a clinical-stage biotech company focused on the development of small-molecule antivirals for Chronic Hepatitis B. ContraVir has developed a strong Hepatitis B pipeline consisting of two small-molecule antiviral agents. With a novel cyclophilin inhibitor and a next-generation reverse transcriptase inhibitor, ContraVir hopes to become the first drug company to bring the first-of-its-kind antiviral combination therapy to the market for the treatment of Hepatitis B. Unlike Hepatitis C or HIV, a small-molecule antiviral combination therapy regimen has not yet been developed for Hepatitis B. ContraVir believes that if approved by the FDA, their small-molecule multi-antiviral agent combination therapy approach can lead to a dramatic therapeutic improvement over the current standard of care. Furthermore, the market has disregarded that ContraVir’s drug candidates can also be utilized for the potential treatment of other diseases and conditions including HIV-1. With the market ignoring their full potential, ContraVir’s stock price has continued to fall to all-time lows. Due to the collapse in stock price that began well over a year ago, ContraVir is now faced with a very low market cap and a NASDAQ price listing requirement violation. Despite their short-term troubles, ContraVir can be an excellent investment opportunity for those willing to take a speculative risk now or those willing to play it safer by waiting out the storm.
Best Biotech Stocks To Invest In Right Now: NovoCure Limited(NVCR)
- [By Chris Lange]
NocoCure Ltd. (NASDAQ: NVCR) is scheduled to release its fourth-quarter earnings report on February 22 as well. The consensus estimates call for a net loss of $0.11 per share and $53.52 million in revenue. The same period of last year had a net loss of $0.26 per share and $30.24 million in revenue. Shares of Novocure most recently closed at $21.50, with a consensus price target of $27.00 and a 52-week range of $6.75 to $24.15.
- [By Brian Feroldi]
After the company reported first-quarter results, shares of NovoCure (NASDAQ:NVCR), a medical device company focused on cancer, jumped as much as 10% in afternoon trading on Thursday. Shares closed the day up more than 9%.
- [By Lee Jackson]
This stock has been on a roll and looks ready to break out. NovoCure Ltd. (NASDAQ: NVCR) develops and commercializes treatments for solid tumor cancer therapy called the tumor treating fields (TTFields). Its markets its proprietary TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
Best Biotech Stocks To Invest In Right Now: Nicholas Financial Inc.(NICK)
- [By Ethan Ryder]
Nicholas Financial (NASDAQ: NICK) and Encore Capital Group (NASDAQ:ECPG) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
- [By Stephan Byrd]
Nicholas Financial (NASDAQ: NICK) and CPI Card Group (NASDAQ:PMTS) are both small-cap finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
- [By Max Byerly]
CPI Card Group (NASDAQ: PMTS) and Nicholas Financial (NASDAQ:NICK) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Best Biotech Stocks To Invest In Right Now: Sun Hydraulics Corporation(SNHY)
- [By Neha Chamaria]
When Sun Hydraulics Corporation (NASDAQ:SNHY) reported its first-quarter 2018 numbers on May 7, the one thing that stood out in the earnings report was its top-line growth. Strong demand for industrial valves and electronics instrumentation combined with Sun Hydraulics’ opportunistic growth moves encouraged the company to upgrade its full-year sales outlook.